252 related articles for article (PubMed ID: 28420650)
61. The influence of ligand-activated LXR on primary human trophoblasts.
Larkin JC; Sears SB; Sadovsky Y
Placenta; 2014 Nov; 35(11):919-24. PubMed ID: 25255963
[TBL] [Abstract][Full Text] [Related]
62. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma.
Na TY; Shin YK; Roh KJ; Kang SA; Hong I; Oh SJ; Seong JK; Park CK; Choi YL; Lee MO
Hepatology; 2009 Apr; 49(4):1122-31. PubMed ID: 19105208
[TBL] [Abstract][Full Text] [Related]
63. PPARα-LXR as a novel metabolostatic signalling axis in skeletal muscle that acts to optimize substrate selection in response to nutrient status.
Caton PW; Holness MJ; Bishop-Bailey D; Sugden MC
Biochem J; 2011 Aug; 437(3):521-30. PubMed ID: 21609322
[TBL] [Abstract][Full Text] [Related]
64. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters.
Bilz S; Samuel V; Morino K; Savage D; Choi CS; Shulman GI
Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E716-22. PubMed ID: 16291572
[TBL] [Abstract][Full Text] [Related]
65. The liver X receptor (LXR) and its target gene ABCA1 are regulated upon low oxygen in human trophoblast cells: a reason for alterations in preeclampsia?
Plösch T; Gellhaus A; van Straten EM; Wolf N; Huijkman NC; Schmidt M; Dunk CE; Kuipers F; Winterhager E
Placenta; 2010 Oct; 31(10):910-8. PubMed ID: 20709391
[TBL] [Abstract][Full Text] [Related]
66. Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis.
Feng K; Ma C; Liu Y; Yang X; Yang Z; Chen Y; Xu T; Yang C; Zhang S; Li Q; Wei Z; Zhao D; Zeng P; Han J; Gao J; Chen Y; Duan Y
Theranostics; 2021; 11(6):2634-2654. PubMed ID: 33456564
[No Abstract] [Full Text] [Related]
67. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles.
Grefhorst A; Elzinga BM; Voshol PJ; Plösch T; Kok T; Bloks VW; van der Sluijs FH; Havekes LM; Romijn JA; Verkade HJ; Kuipers F
J Biol Chem; 2002 Sep; 277(37):34182-90. PubMed ID: 12097330
[TBL] [Abstract][Full Text] [Related]
68. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.
Guo Y; Yuan W; Yu B; Kuai R; Hu W; Morin EE; Garcia-Barrio MT; Zhang J; Moon JJ; Schwendeman A; Eugene Chen Y
EBioMedicine; 2018 Feb; 28():225-233. PubMed ID: 29361501
[TBL] [Abstract][Full Text] [Related]
69. Ozone-derived Oxysterols Affect Liver X Receptor (LXR) Signaling: A POTENTIAL ROLE FOR LIPID-PROTEIN ADDUCTS.
Speen AM; Kim HH; Bauer RN; Meyer M; Gowdy KM; Fessler MB; Duncan KE; Liu W; Porter NA; Jaspers I
J Biol Chem; 2016 Nov; 291(48):25192-25206. PubMed ID: 27703007
[TBL] [Abstract][Full Text] [Related]
70. Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1α-FGF21 axis in mice.
Aljohani A; Khan MI; Bonneville A; Guo C; Jeffery J; O'Neill L; Syed DN; Lewis SA; Burhans M; Mukhtar H; Ntambi JM
J Biol Chem; 2019 Dec; 294(51):19475-19485. PubMed ID: 31690632
[TBL] [Abstract][Full Text] [Related]
71. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype.
Lund EG; Peterson LB; Adams AD; Lam MH; Burton CA; Chin J; Guo Q; Huang S; Latham M; Lopez JC; Menke JG; Milot DP; Mitnaul LJ; Rex-Rabe SE; Rosa RL; Tian JY; Wright SD; Sparrow CP
Biochem Pharmacol; 2006 Feb; 71(4):453-63. PubMed ID: 16325781
[TBL] [Abstract][Full Text] [Related]
72. NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-α and LXR agonists.
Srivastava RAK; Cefalu AB; Srivastava NS; Averna M
Mol Cell Biochem; 2020 Oct; 473(1-2):247-262. PubMed ID: 32661772
[TBL] [Abstract][Full Text] [Related]
73. Apelin protects against liver X receptor-mediated steatosis through AMPK and PPARα in human and mouse hepatocytes.
Huang J; Kang S; Park SJ; Im DS
Cell Signal; 2017 Nov; 39():84-94. PubMed ID: 28821440
[TBL] [Abstract][Full Text] [Related]
74. Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios.
Peter A; Cegan A; Wagner S; Lehmann R; Stefan N; Königsrainer A; Königsrainer I; Häring HU; Schleicher E
Clin Chem; 2009 Dec; 55(12):2113-20. PubMed ID: 19850634
[TBL] [Abstract][Full Text] [Related]
75. Identification of MIG12 as a mediator for stimulation of lipogenesis by LXR activation.
Inoue J; Yamasaki K; Ikeuchi E; Satoh S; Fujiwara Y; Nishimaki-Mogami T; Shimizu M; Sato R
Mol Endocrinol; 2011 Jun; 25(6):995-1005. PubMed ID: 21474539
[TBL] [Abstract][Full Text] [Related]
76. Liver X receptor α promotes the synthesis of monounsaturated fatty acids in goat mammary epithelial cells via the control of stearoyl-coenzyme A desaturase 1 in an SREBP-1-dependent manner.
Yao DW; Luo J; He QY; Xu HF; Li J; Shi HB; Wang H; Chen Z; Loor JJ
J Dairy Sci; 2016 Aug; 99(8):6391-6402. PubMed ID: 27209141
[TBL] [Abstract][Full Text] [Related]
77. Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics.
Li N; Wang X; Xu Y; Lin Y; Zhu N; Liu P; Lu D; Si S
Mol Pharmacol; 2017 Apr; 91(4):264-276. PubMed ID: 28087808
[TBL] [Abstract][Full Text] [Related]
78. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling.
Yoshikawa T; Ide T; Shimano H; Yahagi N; Amemiya-Kudo M; Matsuzaka T; Yatoh S; Kitamine T; Okazaki H; Tamura Y; Sekiya M; Takahashi A; Hasty AH; Sato R; Sone H; Osuga J; Ishibashi S; Yamada N
Mol Endocrinol; 2003 Jul; 17(7):1240-54. PubMed ID: 12730331
[TBL] [Abstract][Full Text] [Related]
79. [Activation of liver X receptor regulates fatty acid synthase expression in diabetic liver].
Wang B; Cheng LJ; Gao ZN; Zhang XY; Huo M; Zhang DJ; Wu J; Wei MF
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):848-52. PubMed ID: 18756992
[TBL] [Abstract][Full Text] [Related]
80. Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?
Wu G; Wang Q; Xu Y; Li J; Zhang H; Qi G; Xia Q
Cell Death Dis; 2019 May; 10(6):416. PubMed ID: 31138790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
